Dermata Therapeutics Inc. (DRMAW)
0.01
-0.01 (-42.53%)
At close: Jan 14, 2025, 9:00 PM
0.01
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 0.01 |
| Market Cap | 2.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.156 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.02 |
| Volume | 424 |
| Avg. Volume (20D) | 0 |
| Open | 0.01 |
| Previous Close | 0.02 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.01 - 0.01 |
| Beta | undefined |
About DRMAW
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMAW
Website http://www.dermatarx.com